The accumulation of hnRNP K and SET mRNA in APL patient samples, during the diagnostic phase, in addition to the reduction in hnRNP K and SET during the chemotherapy phase, suggests not only the involvement of both genes in the leukemogenesis of APL, but also that hnRNP K and SET could be useful as prognostic indicators or treatment response biomarkers. The gene discussed is HNRNPK; the disease is acute promyelocytic leukemia.